› Forums › General Melanoma Community › Just Finished 4th Opdivo/Yervoy Infusion (Intransit Lesions)
- This topic has 4 replies, 3 voices, and was last updated 6 years, 2 months ago by
dmturner.
- Post
-
- March 19, 2017 at 4:14 pm
Finished my 4th Opdivo/yervoy infusion on Thursday. I do have intransit lesions (about 12-15) on my right foot close to my primary that have yet to shrink. My doc order scans (PET or CT) depending on insurance approval and made an appointment in 3 weeks to do Opdivo full dose only every 2 weeks. My question is these pesky lesions (blister looking things). Any one else have them? I have read about T-Vec and my doctor mentioned it but he wants to see improvement in the lymph nodes that are effected with melanoma right now and then maybe the lesions are just slow to respond and then we talk about the injections.
I have read only 10% of melanoma patients get intransit lesions. Just seems like the infusion is like a fertilizer and they just keep popping up. The doc also said I might have blockage in my lymph nodes that is keeping them from cleaning/clearing out. Whatever that means.
Donna
- Replies
-
-
- March 20, 2017 at 11:30 pm
You and David on the forum are about at the same place!!!https://www.melanoma.org/find-support/patient-community/mpip-melanoma-patients-information-page/need-help-non-v600-mutation
-
- March 20, 2017 at 11:32 pm
-
- March 22, 2017 at 12:00 am
Here's a post: PV-10 followed by radiation = ORR of 86% in in-transit, dermal and sub q melanoma that may interest you (there are multiple links within and a zillion posts about T-VEC and other intralesionals on my blog, use the search bubble if interested):
I wish you well. Celeste
-
- March 25, 2017 at 2:18 pm
Thank you both!! I still do not know why these are not responding to the combo of Opdivo/Yervoy. They seem to be getting worse since I posted here. I do have my next PET scan on 3/31/2017 and next treatment (if PET scan allows) on Monday 4/3/2017, Opdivo only at higher dose.
Donna
-
- You must be logged in to reply to this topic.